G. Gottskálksson

The use of implantable cardioverter defibrillators in Iceland: a retrospective population based study

D. Arnar, M. Leósdóttir, Margret Vigfusdottir, 2006, BMC cardiovascular disorders.

Community screening for glucose intolerance in middle-aged Icelandic men. Deterioration to diabetes over a period of 71/2 years.

O. Olafsson, N. Sigfússon, G. Sigurdsson, 2009, Acta medica Scandinavica.

Plasma n‐3 and n‐6 fatty acids and the incidence of atrial fibrillation following coronary artery bypass graft surgery

D. Arnar, R. Palsson, G. Skuladottir, 2011, European journal of clinical investigation.

Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.

D. Gudbjartsson, J. Gulcher, A. Kong, 2005, JAMA.

Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery?

D. Arnar, R. Palsson, G. Skuladottir, 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Health-related quality of life of patients with implantable cardioverter defibrillators compared with that of pacemaker recipients.

E. Sigurdsson, D. Arnar, M. Leósdóttir, 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

The use of implantable cardioverter defibrillators in Iceland: a retrospective population based study.

D. Arnar, M. Leósdóttir, Margret Vigfusdottir, 2006, BMC Cardiovascular Disorders.

Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.

D. Gudbjartsson, J. Gulcher, A. Kong, 2005, Journal of the American Medical Association (JAMA).